Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
- Published In:
- Diabetes care, 43(6), 1352-1355 (2020)
- Authors:
- Hartman, Mark L(2), Sanyal, Arun J(3), Loomba, Rohit(5), Wilson, Jonathan M, Nikooienejad, Amir, Bray, Ross, Karanikas, Chrisanthi A, Duffin, Kevin L, Robins, Deborah A, Haupt, Axel
- Database ID:
- RPEP-04843
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04843APA
Hartman, Mark L; Sanyal, Arun J; Loomba, Rohit; Wilson, Jonathan M; Nikooienejad, Amir; Bray, Ross; Karanikas, Chrisanthi A; Duffin, Kevin L; Robins, Deborah A; Haupt, Axel. (2020). Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.. Diabetes care, 43(6), 1352-1355. https://doi.org/10.2337/dc19-1892
MLA
Hartman, Mark L, et al. "Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.." Diabetes care, 2020. https://doi.org/10.2337/dc19-1892
RethinkPeptides
RethinkPeptides Research Database. "Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepa..." RPEP-04843. Retrieved from https://rethinkpeptides.com/research/hartman-2020-effects-of-novel-dual
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.